Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center at Dallas, 75390-8593, USA. john.minna@utsouthwestern.edu
Nature reviews. Drug discovery 2005 MayErlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor receptor, was approved by the US FDA in November 2004 for the treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy regimen. It is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.
John D Minna, Jonathan Dowell. Erlotinib hydrochloride. Nature reviews. Drug discovery. 2005 May;Suppl:S14-5
PMID: 15962526
View Full Text